Nivolumab + Relatlimab Posts 52% 4-Year OS in First-Line Advanced Melanoma

Nivolumab (PD-1) plus relatlimab (LAG-3) fixed-dose (Opdualag) outperformed nivolumab alone in the phase 2/3 RELATIVITY-047 trial (n = 714 treatment-naïve stage III/IV melanoma): 4-year PFS 30.6% vs 23.6%, OS 52.0% vs 42.8%, and ORR 43.9% vs 33.4%. Grade 3-4 treatment-related adverse events were 21% versus 11%, markedly lower than the 59% seen with nivolumab + ipilimumab in CheckMate 067, with no new safety signals.